U.S. Markets closed

BeyondSpring Inc. (BYSI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
14.83+0.71 (+5.03%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close14.12
Open14.05
Bid14.12 x 800
Ask14.98 x 1000
Day's Range13.76 - 15.50
52 Week Range9.38 - 21.50
Volume189,099
Avg. Volume115,681
Market Cap452.211M
Beta (5Y Monthly)0.95
PE Ratio (TTM)N/A
EPS (TTM)-1.93
Earnings DateSep 03, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est36.75
  • GlobeNewswire

    Seed Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer

    “Molecular Glue” Protein Degradation Serves as Alternative Approach for Difficult-to-Treat DiseasesNEW YORK, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Seed Therapeutics Inc. (the “Company” or “Seed Therapeutics”), a global research company and BeyondSpring subsidiary focused on harnessing and engineering “molecular glue,” a targeted protein degradation (TPD) platform to attack previously believed undruggable targets, today announced the Company’s appointment of Edward Dongheng Liu as Chief Financial Officer. TPD technology targets diseases that cannot be treated with traditional pharmaceutical approaches. About 70 percent of protein targets that are believed to contribute to causing disease have been considered undruggable. Seed Therapeutics employs a world-leading molecular glue platform, which re-wires the cellular ubiquitination system to potentially target any disease-causing proteins.“Seed Therapeutics is one of the few global companies leading the charge in molecular glue-induced protein degradation research,” said Dr. Lan Huang, CEO, Seed Therapeutics. “I am particularly close to this field, as I solved the first E2-E3 ligase in the world 20 years ago when I was a research fellow at Memorial Sloan Kettering Cancer Center. I am inspired to see the TPD field blossoming into a major force behind current innovative drug discovery efforts. As CFO, Edward will lead Seed Therapeutics’ financial efforts and strengthen the Company’s global leadership in the TPD field. His vast global experience in investment banking, corporate development and entrepreneurship will be crucial to the Company’s success.”Mr. Liu has served as BeyondSpring’s CFO since 2018 and played an instrumental role in its overall financial strategies and activities. He successfully enhanced BeyondSpring’s shareholder base, built strong investor and banking relationships and significantly improved the stock’s liquidity. Additionally, he has been an investor in BeyondSpring since 2016. Before joining BeyondSpring, Mr. Liu served as Partner and Executive Director at Epiphron Capital, a healthcare-focused private equity firm, as well as held leadership positions at global financial institutions that include Senior Vice President and Vice President of Investment Banking and Capital Markets at Jefferies and Vice President of Investment Banking at J.P. Morgan. Mr. Liu has led financing and M&A transactions for clients across sectors, with a total transaction value exceeding $30 billion.“Seed Therapeutics’ differentiated molecular glue protein degradation research platform will enable the discovery of new therapies to treat diseases that do not currently have solutions,” added Mr. Liu, who also serves as CFO, China, for BeyondSpring. “My new responsibilities at Seed Therapeutics will further allow us to help bring innovative medicines to patients in need where current therapies fall short.”To learn more, please visit www.seedtherapeutics.com.About Seed Therapeutics Seed Therapeutics, a subsidiary of BeyondSpring Inc. (NASDAQ: BYSI), is a global research company focused on harnessing and engineering “molecular glue” in targeted protein degradation to attack previously believed undruggable targets. Backed by a comprehensive intellectual property portfolio, Seed Therapeutics' mission is to positively impact human health by creating novel protein degradation therapeutics to treat various severe diseases that currently have limited options for patients and their families. Through ongoing collaborations with world-leading academic experts in the field, Seed Therapeutics is establishing a growing pipeline of novel drug candidates on a path to potential clinical and commercial success.About Protein Degradation The majority of approved treatments for diseases act by binding molecular targets inside or outside of cells to impact target-related signaling or actions. The cellular targets of drugs and drug candidates discovered with this typical strategy predominately bind to a specific pocket of the targeted protein structure to inhibit the function of disease-causing proteins. Importantly, more than 70 percent of proteins thought to be involved in diseases are likely to be “undruggable,” as they do not have the pockets for small molecular binding, which this drug development strategy will benefit. Therapeutic development in many serious indications has, therefore, suffered due to a lack of proteins that are druggable, rather than a lack of understanding the disease’s biology.Seed Therapeutics is overcoming this challenge by developing novel therapies that aim to “degrade” disease-causing proteins, such as the mutant KRAS or proteins responsible for resistance to other therapies, to inhibit their function. This groundbreaking strategy has the potential to offer meaningful benefits to millions of patients suffering from serious conditions, from cancer to CNS diseases to infectious diseases.Cautionary Note Regarding Forward-Looking Statements This press release includes forward-looking statements that are not historical facts. Words such as "will," "expect," "anticipate," "plan," "believe," "design," "may," "future," "estimate," "predict," "objective," "goal," or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company's future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet our expectations regarding the potential safety, the ultimate efficacy or clinical utility of our product candidates, increased competition in the market, and other risks described in BeyondSpring’s most recent Form 20-F on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.Media Contacts Caitlin Kasunich / Raquel Cona KCSA Strategic Communications 212.896.1241 / 212.896.1276 ckasunich@kcsa.com / rcona@kcsa.com

  • GlobeNewswire

    BeyondSpring Forms Partnership Advisory Committee Comprised of Industry Veterans

    Former Forty Seven and Roche Senior Executives to Support Partnering EffortsNEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) --  BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology and chemotherapy-induced neutropenia therapies, announced today that it has formed a Partnership Advisory Committee comprised of former multi-national pharmaceutical veterans and industry leaders. The committee is tasked with supporting BeyondSpring’s business development activities related to its lead asset, Plinabulin, and other pipeline assets. Mukul Agarwal, former Vice President, Corporate Development, at Forty Seven, Inc., and Dr. Daniel Zabrowski, former Global Head of Pharma Partnering at Roche and current BeyondSpring Board member, have been appointed as initial members of the committee. The Company expects to name additional members over time. “As BeyondSpring nears submission of Plinabulin’s New Drug Application (NDA) and commercialization, having access to industry veterans who bring to bear track records of striking successful partnerships is of the utmost importance,” said Dr. Huang. “We are especially grateful to have Mr. Agarwal join our committee, as he was instrumental in Gilead’s acquisition of Forty Seven. We will rely on the guidance of Mr. Agarwal and Dr. Zabrowski to help BeyondSpring develop meaningful partnerships for Plinabulin and our other pipeline assets that greatly benefit patients and deliver long-term value to shareholders.”Mr. Agarwal has over 20 years of experience working with both multi-national pharmaceutical and small biotech companies. He currently serves as ReCode Therapeutics’ Chief Business Officer. Previously, he was Vice President, Corporate Development, at Forty Seven, which Gilead acquired for $4.9 billion in March 2020. Prior to Forty Seven, Mr. Agarwal served as Vice President, Corporate Development and Strategy, at Revance Therapeutics, and Senior Director, Business Development and Licensing, at Anacor Pharmaceuticals, which Pfizer acquired for $5.2 billion. He was also Director, Global Business Development and Licensing, at Forest Pharmaceuticals (acquired by Allergan, now AbbVie) and served in other roles at MedImmune (now AstraZeneca) and GlaxoSmithKline.Dr. Zabrowski previously worked for more than 20 years at Roche in a number of key global leadership positions, including Global Head of Regulatory Affairs, Global Head of Development Operations and Global Head of Pharma Partnering. During his tenure in business development, Dr. Zabrowski and his teams executed more than 300 acquisition and partnership deals. Currently, he serves as a Venture Partner at Decheng Capital.“BeyondSpring has reached an important inflection point for the Company,” added Mr. Agarwal. “After recently receiving the Breakthrough Therapy Designation, BeyondSpring is expected to file an NDA for Plinabulin in the near-term, which I am hopeful will result in a rapid approval that allows us to help many patients in need.”About BeyondSpring Headquartered in New York, BeyondSpring is a global biopharmaceutical company focused on the development of innovative immuno-oncology and chemotherapy-induced neutropenia therapies to improve clinical outcomes. BeyondSpring’s first-in-class lead immune asset, Plinabulin, is a potent antigen-presenting cell inducer. It is currently in Phase 3 clinical trials for two severely unmet medical needs indications: one is for the prevention of chemotherapy-induced neutropenia (CIN), the most frequent cause for a chemotherapy regimen dose’s decrease, delay, downgrade or discontinuation, which can lead to suboptimal clinical outcomes. Plinabulin recently received a Breakthrough Therapy Designation from both the U.S. FDA and China’s NMPA for the CIN indication. The other indication is non-small cell lung cancer treatment in EGFR wild-type patients. As a “pipeline drug,” Plinabulin is in various I/O combination studies to boost PD-1 / PD-L1 antibody anti-cancer effects. In addition to Plinabulin, BeyondSpring’s extensive pipeline includes three pre-clinical immuno-oncology assets and a drug discovery platform dubbed “molecular glue” that uses the protein degradation pathway.Cautionary Note Regarding Forward-Looking Statements This press release includes forward-looking statements that are not historical facts. Words such as "will," "expect," "anticipate," "plan," "believe," "design," "may," "future," "estimate," "predict," "objective," "goal," or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company's future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet our expectations regarding the potential safety, the ultimate efficacy or clinical utility of our product candidates, increased competition in the market, and other risks described in BeyondSpring’s most recent Form 20-F on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.Media Contacts Caitlin Kasunich / Raquel Cona KCSA Strategic Communications 212.896.1241 / 212.896.1276 ckasunich@kcsa.com / rcona@kcsa.com

  • GlobeNewswire

    JAMA Oncology Highlights Plinabulin's Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy

    NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology therapies to transform the lives of patients with unmet medical needs, today announced that the Company’s manuscript, titled “Efficacy of Plinabulin vs. Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer,” has been published in JAMA Oncology, the American Medical Association’s peer-reviewed journal. The manuscript analyzed BeyondSpring’s Phase 2 portion of its PROTECTIVE-1 (Study 105) randomized clinical trial, which consisted of four treatment arms and was conducted in 19 treatment centers in the U.S., China, Russia and Ukraine from April 2017 through March 2018, with Covance serving as its contract research organization. Key primary and secondary endpoints were calculated using objective data, such as the absolute neutrophil count and platelet counts, which were based on validated assays conducted at Covance’s central labs in three continents. Participants were adult patients with non-small cell lung cancer (NSCLC) whose cancer had progressed after platinum-based chemotherapy. The objective was to assess the efficacy and safety of the Company’s lead asset, Plinabulin, compared with Pegfilgrastim, a long-lasting G-CSF, which is currently the predominant therapy for chemotherapy-induced neutropenia (CIN) prevention.The protocols were as follows: * All NSCLC patients (n=55) received docetaxel (75 mg/m2) on Day 1 and were randomly assigned to four arms: three dose levels of Plinabulin (5, 10 or 20 mg/m2) monotherapy on Day 1 or Pegfilgrastim (6 mg) monotherapy on Day 2. Patients were treated every 21 days for four chemotherapy cycles.Key results included: * Plinabulin’s CIN effect in terms of Grade 4 frequency was dose-dependent, and the 20 mg/m2 (or 40 mg fixed dose) was selected as the Phase 3 dose. * Plinabulin as a single agent was equally effective as Pegfilgrastim for preventing Grade 4 neutropenia and infections. * In contrast to Pegfilgrastim, patients who received Plinabulin maintained their overall quality of life (p<0.001) and experienced significantly less bone pain and less thrombocytopenia.“The data presented demonstrates that Plinabulin – a novel, non-G-CSF small molecule with anticancer activity – has potent neutropenia prevention effects,” said Dr. Douglas Blayney, Principal Investigator of BeyondSpring’s CIN program with Plinabulin. “The results show the promise that Plinabulin has to deliver relief to cancer patients suffering around the world.”“The results of this study validate Plinabulin’s strength and its potent ability to prevent CIN in cancer patients,” added Dr. Ramon Mohanlal, BeyondSpring’s Chief Medical Officer and Executive Vice President, Research and Development. “This study, coupled with the breakthrough designation granted to our CIN program from both the U.S. FDA and China NMPA, is highly encouraging for our pending New Drug Application filings in both countries.”To access the full e-publication, please visit: https://jamanetwork.com/journals/jamaoncology/article-abstract/2770700.About BeyondSpring Headquartered in New York, BeyondSpring is a global, clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to improve clinical outcomes for patients with high unmet medical needs. BeyondSpring’s first-in-class lead immune asset, Plinabulin, is a potent antigen-presenting cell (APC) inducer. It is currently in two Phase 3 clinical trials for two severely unmet medical needs indications: one is for the prevention of chemotherapy-induced neutropenia (CIN), the most frequent cause for a chemotherapy regimen dose’s decrease, delay, downgrade or discontinuation, which can lead to suboptimal clinical outcomes. The other is for non-small cell lung cancer (NSCLC) treatment in EGFR wild-type patients. As a “pipeline drug,” Plinabulin is in various I/O combination studies to boost PD-1 / PD-L1 antibody anti-cancer effects. In addition to Plinabulin, BeyondSpring’s extensive pipeline includes three pre-clinical immuno-oncology assets and a drug discovery platform dubbed “molecular glue” that uses the protein degradation pathway. About Plinabulin Plinabulin, BeyondSpring’s lead asset, is a differentiated immune and stem cell modulator. Plinabulin is currently in late-stage clinical development to increase overall survival in cancer patients, as well as to alleviate chemotherapy-induced neutropenia (CIN). The durable anticancer benefits of Plinabulin have been associated with its effect as a potent antigen-presenting cell (APC) inducer (through dendritic cell maturation) and T-cell activation (Chem and Cell Reports, 2019). Plinabulin’s CIN data highlights the ability to boost the number of hematopoietic stem / progenitor cells (HSPCs), or lineage-/cKit+/Sca1+ (LSK) cells in mice. Effects on HSPCs could explain the ability of Plinabulin to not only treat CIN but also to reduce chemotherapy-induced thrombocytopenia and increase circulating CD34+ cells in patients.Cautionary Note Regarding Forward-Looking Statements This press release includes forward-looking statements that are not historical facts. Words such as "will," "expect," "anticipate," "plan," "believe," "design," "may," "future," "estimate," "predict," "objective," "goal," or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company's future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet our expectations regarding the potential safety, the ultimate efficacy or clinical utility of our product candidates, increased competition in the market, and other risks described in BeyondSpring’s most recent Form 20-F on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.Media Contacts Caitlin Kasunich / Raquel Cona KCSA Strategic Communications ckasunich@kcsa.com / rcona@kcsa.com